Flk-1/KDR/VEGFR2 Antibody (A-3): sc-6251

VEGFR2 Antibody (A-3) is a mouse monoclonal IgG1 kappa light chain antibody raised against amino acids 1158-1345 mapping at the C-terminus of the VEGFR2 of mouse origin. VEGFR2 monoclonal antibody (A-3) targets the C-terminal region of VEGFR2, ensuring effective binding and detection across mouse, rat, and human species. VEGFR2 is a pivotal receptor tyrosine kinase that plays a fundamental role in angiogenesis, the process by which new blood vessels form from existing vasculature. By mediating the effects of VEGF ligands, VEGFR2 regulates endothelial cell proliferation, migration, and survival, making it essential for both normal physiological processes such as development and wound healing, as well as pathological conditions like cancer, where angiogenesis supports tumor growth and metastasis. VEGFR2 monoclonal antibody (A-3) is versatile in its applications, suitable for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry, thereby facilitating a wide range of research and diagnostic studies. VEGFR2 monoclonal antibody (A-3) is available in both non-conjugated form and with multiple conjugates, including horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and Alexa Fluor® variants, providing flexibility to meet diverse experimental requirements.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Flk-1/KDR/VEGFR2 Antibody (A-3) References:

1. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.  |  de Vries, C., et al. 1992. Science. 255: 989-91. PMID: 1312256
2. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit.  |  Matthews, W., et al. 1991. Proc Natl Acad Sci U S A. 88: 9026-30. PMID: 1717995
3. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family.  |  Shibuya, M., et al. 1990. Oncogene. 5: 519-24. PMID: 2158038
4. VEGF-Independent Angiogenic Factors: Beyond VEGF/VEGFR2 Signaling.  |  Eguchi, R., et al. 2022. J Vasc Res. 59: 78-89. PMID: 35152220
5. Targeting VEGF-A/VEGFR2 Y949 Signaling-Mediated Vascular Permeability Alleviates Hypoxic Pulmonary Hypertension.  |  Zhou, W., et al. 2022. Circulation. 146: 1855-1881. PMID: 36384284
6. KIF13B mediates VEGFR2 recycling to modulate vascular permeability.  |  Cho, HD., et al. 2023. Cell Mol Life Sci. 80: 91. PMID: 36928770
7. Mechanotransduction via endothelial adhesion molecule CD31 initiates transmigration and reveals a role for VEGFR2 in diapedesis.  |  Fu, T., et al. 2023. Immunity. 56: 2311-2324.e6. PMID: 37643615
8. Anti-VEGFR2 F(ab')2 drug conjugate promotes renal accumulation and glomerular repair in diabetic nephropathy.  |  Liu, D., et al. 2023. Nat Commun. 14: 8268. PMID: 38092739
9. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis.  |  Millauer, B., et al. 1993. Cell. 72: 835-46. PMID: 7681362
10. Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth.  |  Peters, KG., et al. 1993. Proc Natl Acad Sci U S A. 90: 8915-9. PMID: 7692439
11. The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor.  |  Galland, F., et al. 1993. Oncogene. 8: 1233-40. PMID: 8386825
12. NYK/FLK-1: a putative receptor protein tyrosine kinase isolated from E10 embryonic neuroepithelium is expressed in endothelial cells of the developing embryo.  |  Oelrichs, RB., et al. 1993. Oncogene. 8: 11-8. PMID: 8423988

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Flk-1/KDR/VEGFR2 Antibody (A-3) has 579 citations in a variety of scientific publications.

Primary antibodies like Anti-Flk-1/KDR/VEGFR2 Antibody (A-3) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Flk-1/KDR/VEGFR2 Antibody (A-3) Specifications

Alternate Product Name: VEGFR2

Product Clone Name: A-3

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 1158-1345

Epitope Target: VEGFR2

Epitope Species: mouse

Product Reactivity/Detection: VEGFR2

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P)

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 579 citations in various scientific publications

Available Conjugates/Forms for Flk-1/KDR/VEGFR2 Antibody (A-3): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin, X: TransCruz Reagent